Cancer Research 09 AM Call for Abstracts SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 67, 429-432, January 15, 2007. doi: 10.1158/0008-5472.CAN-06-2871
© 2007 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, T.-C.
Right arrow Articles by Kirn, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, T.-C.
Right arrow Articles by Kirn, D.
Related Collections
Right arrow Clinical Research
Right arrow Clinical Research: Clinical Trials

Reviews

Systemic Efficacy with Oncolytic Virus Therapeutics: Clinical Proof-of-Concept and Future Directions

Ta-Chiang Liu1 and David Kirn2,3

1 Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 2 JENNEREX Biotherapeutics, Inc., San Francisco, California; and 3 Department of Clinical Pharmacology, University of Oxford Medical School, Oxford, United Kingdom

Requests for reprints: David Kirn, JENNEREX Biotherapeutics, Inc., San Francisco, CA. E-mail: dkirn{at}jennerex.com.

Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed. [Cancer Res 2007;67(2):429–32]




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Libertini, I. Iacuzzo, G. Perruolo, S. Scala, C. Ierano, R. Franco, G. Hallden, and G. Portella
Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus dl922-947
Clin. Cancer Res., October 15, 2008; 14(20): 6505 - 6514.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. V. Shashkova, K. Doronin, J. S. Senac, and M. A. Barry
Macrophage Depletion Combined with Anticoagulant Therapy Increases Therapeutic Window of Systemic Treatment with Oncolytic Adenovirus
Cancer Res., July 15, 2008; 68(14): 5896 - 5904.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Gauvrit, S. Brandler, C. Sapede-Peroz, N. Boisgerault, F. Tangy, and M. Gregoire
Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response
Cancer Res., June 15, 2008; 68(12): 4882 - 4892.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Nagano, J. Y. Perentes, R. K. Jain, and Y. Boucher
Cancer Cell Death Enhances the Penetration and Efficacy of Oncolytic Herpes Simplex Virus in Tumors
Cancer Res., May 15, 2008; 68(10): 3795 - 3802.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Brader, J. Stritzker, C. C. Riedl, P. Zanzonico, S. Cai, E. M. Burnazi, E.R. Ghani, H. Hricak, A. A. Szalay, Y. Fong, et al.
Escherichia coli Nissle 1917 Facilitates Tumor Detection by Positron Emission Tomography and Optical Imaging
Clin. Cancer Res., April 15, 2008; 14(8): 2295 - 2302.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
K. Ozduman, G. Wollmann, J. M. Piepmeier, and A. N. van den Pol
Systemic Vesicular Stomatitis Virus Selectively Destroys Multifocal Glioma and Metastatic Carcinoma in Brain
J. Neurosci., February 20, 2008; 28(8): 1882 - 1893.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Ungerechts, C. Springfeld, M. E. Frenzke, J. Lampe, P. B. Johnston, W. B. Parker, E. J. Sorscher, and R. Cattaneo
Lymphoma Chemovirotherapy: CD20-Targeted and Convertase-Armed Measles Virus Can Synergize with Fludarabine
Cancer Res., November 15, 2007; 67(22): 10939 - 10947.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. S. Reddy, K. D. Burroughs, L. M. Hales, S. Ganesh, B. H. Jones, N. Idamakanti, C. Hay, S. S. Li, K. L. Skele, A.-J. Vasko, et al.
Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus, and the Treatment of Neuroendocrine Cancers
J Natl Cancer Inst, November 7, 2007; 99(21): 1623 - 1633.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T.-C. Liu, H. Wakimoto, R. L. Martuza, and S. D. Rabkin
Herpes Simplex Virus Us3( ) Mutant as Oncolytic Strategy and Synergizes with Phosphatidylinositol 3-Kinase-Akt Targeting Molecular Therapeutics
Clin. Cancer Res., October 1, 2007; 13(19): 5897 - 5902.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.